XERS vs. AGIO, APGE, TARS, AMPH, IOVA, IBRX, IRON, WVE, BLTE, and ARQT
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX), Disc Medicine (IRON), Wave Life Sciences (WVE), Belite Bio (BLTE), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs.
Xeris Biopharma (NASDAQ:XERS) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Agios Pharmaceuticals has a net margin of 2,051.38% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.
Agios Pharmaceuticals received 347 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.76% of users gave Xeris Biopharma an outperform vote while only 67.03% of users gave Agios Pharmaceuticals an outperform vote.
Xeris Biopharma has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
42.8% of Xeris Biopharma shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Xeris Biopharma has higher revenue and earnings than Agios Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma currently has a consensus price target of $4.87, suggesting a potential upside of 52.08%. Agios Pharmaceuticals has a consensus price target of $56.33, suggesting a potential upside of 73.76%. Given Agios Pharmaceuticals' higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Xeris Biopharma.
In the previous week, Agios Pharmaceuticals had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 0 mentions for Xeris Biopharma. Agios Pharmaceuticals' average media sentiment score of 0.36 beat Xeris Biopharma's score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.
Summary
Agios Pharmaceuticals beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free XERS Stock Alerts